Showing 1 - 6 of 6
Persistent link: https://www.econbiz.de/10011812699
Persistent link: https://www.econbiz.de/10010198694
We examine six molecules facing initial loss of US exclusivity (LOE, from patent expiration or challenges) between June 2009 and May 2013 that were among the 50 most prescribed molecules in May 2013. We examine prices per day of therapy (from the perspective of average revenue received by retail...
Persistent link: https://www.econbiz.de/10010969367
Persistent link: https://www.econbiz.de/10010822181
Health care costs represent a nearly 18% of U.S. gross domestic product and 20% of government spending. While there is detailed information on where these health care dollars are spent, there is much less evidence on how this spending affects health. The research in Measuring and Modeling Health...
Persistent link: https://www.econbiz.de/10014479897
We examine six molecules facing initial loss of US exclusivity (LOE, from patent expiration or challenges) between June 2009 and May 2013 that were among the 50 most prescribed molecules in May 2013. We examine prices per day of therapy (from the perspective of average revenue received by retail...
Persistent link: https://www.econbiz.de/10012459174